Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The 80-week trial was double-blinded, meaning neither the participants nor the researchers knew which treatment the participants received
Routine checkups with a medical professional can assist with dose fine-tuning and early side effect identification
Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3-Via Mcl-1/Noxa Axis
With its lemon-based composition and selected ingredients, it offers a practical liquid blend for everyday use
It is prolonged, cumulative exposure that causes measurable degradation
MT-II's published clinical-trial exposure is small
US$ 21.60
US$ 20.93
US$ 24.95
US$ 23.57
